These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 19912519)

  • 1. Antithrombotic effect of enoxaparin in clinically healthy cats: a venous stasis model.
    Van De Wiele CM; Hogan DF; Green HW; Sederquist KD
    J Vet Intern Med; 2010; 24(1):185-91. PubMed ID: 19912519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Xa activity after enoxaparin prophylaxis in hospitalized patients weighing less than fifty-five kilograms.
    Rojas L; Aizman A; Ernst D; Acuña MP; Moya P; Mellado R; Cerda J
    Thromb Res; 2013; 132(6):761-4. PubMed ID: 24521789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
    Turpie AG; Bauer KA; Davidson BL; Fisher WD; Gent M; Huo MH; Sinha U; Gretler DD;
    Thromb Haemost; 2009 Jan; 101(1):68-76. PubMed ID: 19132191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of enoxaparin, a low molecular weight heparin in the prevention of deep vein thrombosis in Nigerian patients after orthopaedic surgery.
    Akanmu AS; Nnodu OE; Giwa SO; Salako LA; Akinsete I; Adebule GT; Adekoya-Cole TO; Odunubi OO
    Afr J Med Med Sci; 2004 Dec; 33(4):335-40. PubMed ID: 15977441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enoxaparin: pharmacokinetics and treatment schedule for cats.
    Mischke R; Schönig J; Döderlein E; Wolken S; Böhm C; Kietzmann M
    Vet J; 2014 Jun; 200(3):375-81. PubMed ID: 24810867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy.
    Lebaudy C; Hulot JS; Amoura Z; Costedoat-Chalumeau N; Serreau R; Ankri A; Conard J; Cornet A; Dommergues M; Piette JC; Lechat P
    Clin Pharmacol Ther; 2008 Sep; 84(3):370-7. PubMed ID: 18431408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients.
    Vincent PD; Albert M; Champagne MC; Zikos T; Boulanger I; Blais L; Williamson DR
    J Crit Care; 2011 Aug; 26(4):347-51. PubMed ID: 21454037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: Comparative study of enoxaparin versus coumarin.
    González-Fajardo JA; Martin-Pedrosa M; Castrodeza J; Tamames S; Vaquero-Puerta C
    J Vasc Surg; 2008 Oct; 48(4):953-9. PubMed ID: 18639417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
    Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
    Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peak plasma anti-Xa levels after first and third doses of enoxaparin in women receiving weight-based thromboprophylaxis following caesarean section: a prospective cohort study.
    Hiscock RJ; Casey E; Simmons SW; Walker SP; Newell PA
    Int J Obstet Anesth; 2013 Nov; 22(4):280-8. PubMed ID: 23958275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis: a randomized controlled pilot trial.
    Louis SG; Van PY; Riha GM; Barton JS; Kunio NR; Underwood SJ; Differding JA; Rick E; Ginzburg E; Schreiber MA
    J Trauma Acute Care Surg; 2014 Apr; 76(4):937-42; discussion 942-3. PubMed ID: 24662855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Factor Xa Activity of Prophylactic Enoxaparin Regimens in Critically Ill Patients.
    Helviz Y; Dzigivker I; Raveh-Brawer D; Hersch M; Zevin S; Einav S
    Isr Med Assoc J; 2016 Feb; 18(2):108-13. PubMed ID: 26979004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients.
    Lin H; Faraklas I; Saffle J; Cochran A
    J Trauma; 2011 Dec; 71(6):1557-61. PubMed ID: 22027887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
    Corder A; Held K; Oschman A
    Pediatr Blood Cancer; 2014 Jun; 61(6):1063-7. PubMed ID: 24375987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
    Priglinger U; Delle Karth G; Geppert A; Joukhadar C; Graf S; Berger R; Hülsmann M; Spitzauer S; Pabinger I; Heinz G
    Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran: new drug. Continue to use heparin, a better-known option.
    Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.
    Feng W; Wu K; Liu Z; Kong G; Deng Z; Chen S; Wu Y; Chen M; Liu S; Wang H
    Thromb Res; 2015 Dec; 136(6):1133-44. PubMed ID: 26498222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
    Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
    N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterisation of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo.
    Stassen JM; Lambeir AM; Vreys I; Deckmyn H; Matthyssens G; Nyström A; Vermylen J
    Thromb Haemost; 1995 Aug; 74(2):655-9. PubMed ID: 8585002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinations of low doses of unfractionated heparin and of low-molecular-weight heparin prevent experimental venous thrombosis.
    Carelli G; Maffei FH; Mattar L; Ferrari IC; Thomazini-Santos IA; de Carvalho LR
    Pathophysiol Haemost Thromb; 2005; 34(6):263-8. PubMed ID: 16772737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.